Phase 4CompletedAge-related condition

Lithium As a Treatment to Prevent Impairment of Cognition in Elders (LATTICE)

Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia

Sponsor
Ariel Gildengers, MD (Academic or other)
Enrollment
83 enrolled
Conditions
Mild Cognitive Impairment
Interventions
Lithium Carbonate; Placebo oral capsule
Ages
adults, older adults
Registry
NCT03185208

Full record on ClinicalTrials.gov

From the registry

Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.

Primary outcomes

  • California Verbal Learning Test II
  • Brief Visuospatial Memory Test - Revised
  • Preclinical Alzheimer Cognitive Composite Composed of Memory and Other Cognitive Tests
  • Glycogen Synthase Kinase-3 Beta (GSK-3β) Activity

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered

Papers citing this trial